Frontier Medicine
CRISPR-терапія переводить генне редагування в регульовану клінічну інфраструктуру
СигналFDA approved Casgevy and Lyfgenia for patients 12 years and older with sickle cell disease; Casgevy is the first FDA-approved treatment using CRISPR/Cas9 genome editing.
ПатернProgrammable biology is becoming a clinical infrastructure problem: the therapy depends on cell processing, genetic modification, quality control, and long-term monitoring, not only on molecular discovery.
НаслідокHealth systems, payers, manufacturers, and treatment centers need operating capacity for high-cost individualized therapies, including traceability, safety follow-up, and access design.
ДіяTrack which platforms can turn gene editing into repeatable clinical operations rather than isolated breakthrough procedures.